

Image

1642

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

**INFORMATION DISCLOSURE
STATEMENT**

Docket Number:
11746/46002

Application Number
10/053,498

Filing Date
January 17, 2002

Examiner

Art Unit
1642

Invention Title

**CONJUGATE HEAT SHOCK PROTEIN-BINDING
PEPTIDES**

Inventor(s)
ROTHMAN et al.

Address to:
Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on

Date: January 22, 2004

By: Lawrence P. Casson by: Mary C. Werner
Lawrence P. Casson (Reg. No. 46,606) Reg. No. 30,333

1. In accordance with the duty of disclosure under 37 C.F.R. § 1.56 and in conformance with the procedures of 37 C.F.R. §§ 1.97 and 1.98 and M.P.E.P. § 609, attorneys for Applicants hereby bring the attached references to the attention of the Examiner. These references are listed on the attached modified PTO Form No. 1449. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.
2. The filing of this Information Disclosure Statement and the attached PTO Form No. 1449, shall not be construed as an admission that the information cited is prior art, or is considered to be material to patentability as defined in 37 C.F.R. § 1.56(b).
3. A copy of each patent, publication or other information listed on the modified PTO form 1449 is enclosed.
4. It is believed that no fees are due in connection with this Information Disclosure Statement. However, should any fees be due, the Commissioner is authorized to charge or credit any over payment to Deposit Account No. 11-0600. A duplicate copy of this communication is enclosed for charging purposes.

Dated: January 22, 2004

By: Mary C. Werner Reg. No. 30,333
Lawrence P. Casson (Reg. No. 46,606)

KENYON & KENYON
One Broadway
New York, N.Y. 10004
(212) 425-7200 (telephone)
(212) 425-5288 (facsimile)

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

Modified PTO Form 1449

JAN 26 2004

Docket Number
11746/46002

Serial No.
10/053,498

Inventor(s)
ROTHMAN et al.

Filing Date
January 17, 2002

Group
1642

U. S. PATENT DOCUMENTS

EXAMINER INITIAL	PATENT NUMBER	PATENT DATE	NAME	CLASS	SUBCLASS	FILING DATE*
	6,048,530	4/11/00	Srivastava			
	6,030,618	2/29/00	Srivastava			
	6,017,540	1/25/00	Srivastava et al.			
	5,961,979	10/5/99	Srivastava			
	5,997,873	12/7/99	Srivastava			
	5,985,270	11/16/99	Srivastava			
	5,935,576	8/10/99	Srivastava			
	5,837,251	11/17/98	Srivastava			
	5,750,119	5/12/98	Srivastava			
	5,541,109	6/30/96	Searfoss			
	5,348,945	9/20/94	Berberian et al.			

* - If pertinent


FOREIGN PATENT DOCUMENTS


EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES N/A NO
-	WO 98/35705	8/20/98	PCT			N/A
-	WO 98/23735	6/4/98	PCT			N/A
-	WO 97/26910	7/31/97	PCT			N/A
-	WO 97/10000	3/20/97	PCT			N/A
-	WO 97/10001	3/20/97	PCT			N/A
-	WO 97/10002	3/20/97	PCT			N/A
-	WO 97/06685	2/27/97	PCT			N/A
-	WO 97/06821	2/27/97	PCT			N/A
-	WO 96/10411	4/11/96	PCT			N/A
-	WO 95/24923	9/21/95	PCT			N/A
-	WO 94/29459	12/22/94	PCT			N/A
-	WO 94/11513	5/26/94	PCT			N/A

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
	- WO 93/17712	9/16/93	PCT			N/A
O P E R A T I O N S	- WO 89/04871	6/1/89	PCT			N/A
JAN 26 2004 PATENT TRADEMARK OFFICE	- 0 538 952	4/28/93	Europe			N/A

OTHER DOCUMENTS

EXAMINER INITIAL	AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.
	Galigniana et al., 1998, Mol. Endo. 12:1903-1913.
	Czar et al., 1997, Biochemistry 36:7776-7785.
	Blachere et al., 1997, J. Exp. Med. 186:1315-1322.
	Tamura et al., 1997, Science 278:117-120.
	Wearsch et al., 1997, J. Biol. Chem. 272:5152-5156.
	Tavaria et al., 1996, Cell Stress and Chaperones 1:23-28.
	Jakob et al., 1996, J. Biol. Chem. 271:10035-10041.
	Rosenberg et al., December 1996, inNovations (newsletter of Novagen, Inc.) No. 6, pp. 1-6
	Auger et al., 1996, Nature Medicine 2:306-310.
	Gilboa, 1996, Seminars in Oncology 23:101-107.
	Minami et al., 1996, J. Biol. Chem. 271:19617-19624.
	Nieland et al., 1996, Proc. Natl. Acad. Sci. USA 93:6135-6139.
	Zhu et al., 1996, Science 272:1606-1614.
	Bauer et al., 1995, Scand. J. Immunol. 42:317-323.
	Blachere and Srivastava, 1995, Seminars in Cancer Biology 6:349-355.
	Edginton, 1995, Bio/Technol. 13:1442-1444.
	Greene et al., 1995, J. Biol. Chem. 270:2967-2978.
	Hohfeld et al., 1995, Cell 83:589-598.
	Lowrie et al., 1995, J. Cell. Biochem, Suppl. 0(19b):220.
	McCarty et al., 1995, J. Mol. Biol. 249:126-137.
	Multhoff et al., 1995, Int. J. Cancer 61:272-279.
	Zhu et al., 1995, Scand. J. Immunol. 42:557-563.
	Whitesell, et al., 1994, Proc. Natl. Acad. Sci. USA 91:8324-8328.
	Gragerov et al., 1994, J. Mol. Biol. 235:133-135.
	Gragerov et al., 1994, J. Mol. Biol. 235:848-854.

EXAMINER INITIAL	AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.
	Barrios et al., 1994, Clin. Exp. Immunol. 98:224-228.
 JAN 26 2004	Barrios et al., 1994, Clin. Exp. Immunol. 98:229-233.
	Del Guidice, 1994, Experientia 50:1061-1066.
	Lowrie et al., 1994, Vaccine 12:1537-1540.
	Nygren et al., 1994, Trends Biotechnol. 12(5):184-188.
	Retzlaff et al., 1994, Infect. Immun. 62:5689-5693.
	Schmid et al., 1994, Science 263:971-973.
	Sato et al., 1994, Proc. Annu. Meet. Am. Assoc. Cancer Res. 35:A2959.
	Silva and Lowrie, 1994, Immunology 82:244-248.
	Srivastava, 1994, Experientia 50:1054-1060.
	Srivastava and Udon, 1994, Current Opinion in Immunology 6:728-732.
	Blond-Elguindi et al., 1993, Cell 75: 717-728.
	DeNagel and Pierce et al., 1993, Critical Reviews in Immunology 13:71:81.
	Lukacs et al., 1993, J. Exp. Med. 178:343-348.
	Mustafa et al., 1993, Infection and Immunity 61:5294-5301.
	Palleros et al., 1993, Nature 365:664-666.
	Perraut, 1993, Clin. Exp. Immunol. 93:382-386.
	Srivastava, 1993, Adv. Cancer Res. 62:153-177.
	Yamamoto et al., 1993, Infection and Immunity 61:2154-2161.
	Nadeau et al., 1992, J. Biol. Chem. 268:1479-1487.
	Nadeau et al., 1992, Protein Science 1:970-979.
	Barrios et al., 1992, Euro. J. Immunol. 22:1365-1372.
	Davidoff et al., 1992, Proc. Natl. Acad. Sci. USA 89:3439-3442.
	Pidoux et al., 1992, EMBO J. 11:1583-1591.
	Lussow et al., 1991, J. Eur. Immunol. 21:2297-2302.
	Srivastava and Maki, 1991, Current Topics in Microbiology and Immunology 167:109-123.
	Flynn et al., 1989, Science 245:385-390.
	Pelham 1988, EMBO J. 7:913-918.
	Munro and Pelham, 1987, Cell, 480:899-907.
	Srivastava et al., 1986, Proc. Natl. Acad. Sci. USA 83:3407-3411.
	Ullrich et al., Proc. 1986, Natl. Acad. Sci. USA 83:3121-3125.
	Von Heijne, 1985, J. Mol. Biol. 184:99-105.

EXAMINER INITIAL	AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.
	Suzue, K. et al., 1996, J. Immunol. 156:873-9.
	Jindal, S., 1996, Trends Biotechnol. 14:17-20.
	Arnold, D. et al., 1995, J. Exp. Med. 182:885-9.
	Suto, R. et al., 1995, Science 269:1585-7.
	Gething, M.-J. et al., 1995, Cold Spring Harb. Symp. Quant. Biol. 60:417-28.
	Tarpay, I. et al., 1994, Immunology 81:222-7.
	Udon, H. et al., 1994, Science 91:3077-81.
	Li, Z. et al., 1993, EMBO J. 12:3143-51.
	Udon, H. et al., 1993, J. Exp. Med. 178:1391-6.
	Moroi, Y., 2000, Proc Natl Acad Sci U S A 2000 Mar 28;97(7):3485-90
	Melnick, J., 1992, Journal of Biochemistry 267:21303-21306
	Dillman et al., 1995, J. Cell. Biochem., Suppl. 19B, p. 190
	Plumier et al., 1995, J. Clin. Invest. 95 (4), pp. 1854-1860
	Little, et al., 1994, Critical Reviews in Eukaryotic Gene Expression, 1994 4(1) p.1-18
	Porgador et al., 1994 Nat. Immun. 13:113-130
	Jaattela, 1995, Int. J. Cancer, 60 (5), pp. 689-693
	Udon, H. et al., 1994, J. Immun. 152, pp.5398-5403
	Pardoll. 1993, Current Opinion in Immunology, 5:719-725
	Mastrangelo et al., 1996, Seminars in Oncology, 23:4-21
	Lukacs et al., 1994, Cancer Gene Therapy, 1:217

Examiner	Date Considered
<p>EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>	